- Home
- MRSN vs BNR Comparison
MRSN vs BNR Comparison
Compare MRSN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- BNR
- Stock Information
- Founded
- MRSN 2001
- BNR 2014
- Country
- MRSN United States
- BNR China
- Employees
- MRSN N/A
- BNR N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- MRSN Health Care
- BNR Health Care
- Exchange
- MRSN Nasdaq
- BNR Nasdaq
- Market Cap
- MRSN 37.0M
- BNR 38.3M
- IPO Year
- MRSN 2017
- BNR 2020
- Fundamental
- Price
- MRSN $7.15
- BNR $8.27
- Analyst Decision
- MRSN Strong Buy
- BNR
- Analyst Count
- MRSN 3
- BNR 0
- Target Price
- MRSN $33.00
- BNR N/A
- AVG Volume (30 Days)
- MRSN 62.6K
- BNR 38.7K
- Earning Date
- MRSN 11-12-2025
- BNR 09-08-2025
- Dividend Yield
- MRSN N/A
- BNR N/A
- EPS Growth
- MRSN N/A
- BNR N/A
- EPS
- MRSN N/A
- BNR N/A
- Revenue
- MRSN $34,769,000.00
- BNR $74,862,782.00
- Revenue This Year
- MRSN N/A
- BNR $136.32
- Revenue Next Year
- MRSN N/A
- BNR N/A
- P/E Ratio
- MRSN N/A
- BNR N/A
- Revenue Growth
- MRSN 16.14
- BNR 5.20
- 52 Week Low
- MRSN $5.21
- BNR $2.18
- 52 Week High
- MRSN $70.75
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- MRSN 47.47
- BNR 51.01
- Support Level
- MRSN $7.04
- BNR $8.30
- Resistance Level
- MRSN $7.49
- BNR $9.55
- Average True Range (ATR)
- MRSN 0.44
- BNR 0.70
- MACD
- MRSN 0.00
- BNR -0.15
- Stochastic Oscillator
- MRSN 36.53
- BNR 24.68
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.